Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;20(1):16-32.
doi: 10.1038/s41571-022-00696-0. Epub 2022 Oct 28.

Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies

Affiliations
Review

Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies

Kenta Kawasaki et al. Nat Rev Clin Oncol. 2023 Jan.

Abstract

Neuroendocrine neoplasms (NENs) can develop in almost any organ and span a spectrum from well-differentiated and indolent neuroendocrine tumours (NETs) to poorly differentiated and highly aggressive neuroendocrine carcinomas (NECs), including small-cell lung cancer (SCLC). These neoplasms are thought to primarily derive from neuroendocrine precursor cells located throughout the body and can also arise through neuroendocrine transdifferentiation of organ-specific epithelial cell types. Hence, NENs constitute a group of tumour types that share key genomic and phenotypic characteristics irrespective of their site of origin, albeit with some organ-specific differences. The establishment of representative preclinical models for several of these disease entities together with analyses of human tumour specimens has provided important insights into crucial aspects of their biology with therapeutic implications. In this Review, we provide a comprehensive overview of the current understanding of NENs of the gastrointestinal system and lung from clinical and biological perspectives. Research on NENs has typically been siloed by the tumour site of origin, and a cross-cutting view might enable advances in one area to accelerate research in others. Therefore, we aim to emphasize that a better understanding of the commonalities and differences of NENs arising in different organs might more effectively inform clinical research to define therapeutic targets and ultimately optimize patient care.

PubMed Disclaimer

References

    1. Bedard, P. L., Hyman, D. M., Davids, M. S. & Siu, L. L. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395, 1078–1088 (2020). - DOI
    1. Flaherty, K. T., Le, D. T. & Lemery, S. Tissue-agnostic drug development. Am. Soc. Clin. Oncol. Educ. Book 37, 222–230 (2017). - DOI
    1. FDA. FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro... (2019).
    1. FDA. FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-g... (2018).
    1. FDA. FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumors https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pemb... (2020).

Publication types

LinkOut - more resources